The combination of motixafortide, KEYTRUDA® and chemotherapy met all trial endpoints, including increasing overall and progression free survival.
List view / Grid view
Filter the results
The recommendation of Adcetris (brentuximab vedotin) represents the first new frontline therapy for systemic anaplastic large cell lymphoma (sALCL) in several decades.
Researchers reveal dose-adjusted (DA) EPOCH-R chemotherapy regimen was effective across all ages of Burkitt lymphoma patients in a Phase II clinical trial.
Novel particles could be incorporated into topical creams to treat dermatological conditions without systemic exposure to drugs.
The European Commission (EC) granted marketing authorisation for Darzalex in combination with bortezomib, thalidomide and dexamethasone (VTd) for multiple myeloma patients.
The US FDA has granted avatrombopag (Doptelet) ODD as around 10 percent of US cancer patients per year experience chemotherapy-induced thrombocytopenia (CIT) with no available treatment.
The FDA and EMA have granted Orphan Drug Designation to zotiraciclib, currently the subject of two separate Phase Ib clinical trials in glioblastoma.
A new drug delivery technology has been developed using nanotubes which can efficiently and precisely target lung cancer cells.
A review of a study on children with liver cancer has shown the effectiveness of Transarterial Radioembolization with Yttrium-90 as a course of treatment...
Cardiac monitoring of high-risk breast cancer patients should be prioritised, after research revealed low rates of heart monitoring seen in the patients receiving trastuzumab.
Senescent, or zombie cells, are being targeted with the development of a new nanocarrier drug delivery system.
Once-daily oral pill could replace preoperative chemotherapy in patient population if validated in larger trials...
Protein inhibits inflammatory response underlying chronic pain processing may provide an alternative to opioids for severe, persistent pain...